This post was originally published on this site Xtandi (enzalutamide), an androgen receptor inhibitor, significantly delays disease progression — as assessed through radiological imaging — or death in metastatic hormone-sensitive prostate cancer (mHSPC) patients, a Phase 3 clinical trial shows. The benefits were seen independently of patients’ initial PSA levels, suggesting that, contrary to prior beliefs, PSA…
Conditions
Conditions
IBI301 (Biosimilar of Rituxan) Meets Primary Endpoints in 2 Clinical Trials in China for B-cell Lymphomas
This post was originally published on this site IBI301, a biosimilar of Rituxan (rituximab), behaves similarly in the body and has a similar efficacy as the original product in patients with B-cell cancers, according to results from two clinical trials in China, IBI301’s co-developers, Innovent Biologics and Eli Lilly, has announced. “The results of clinical…
Prostate Cancer Foundation Puts Patients on Path to Knowledge with Updated Guide, Resources
This post was originally published on this site The Prostate Cancer Foundation (PCF) has released its comprehensive Prostate Cancer Patient Guide with the latest in diagnosis, research, treatments, and lifestyle factors for patients and caregivers. With contributions from leading physicians and scientists, the free guide is aimed at patients who have recently been diagnosed, are…
ADDF Grants $1.5M to Fund U.S. Arm of Phase 2a Trial for Vafidemstat in Alzheimer’s Patients
This post was originally published on this site The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded $1.5 million to Oryzon Genomics to support expanding an ongoing Phase 2a trial assessing the potential of vafidemstat (ORY-2001) in patients with mild to moderate Alzheimer’s disease to the United States. The double-blind, placebo-controlled trial (2017-004893-32), called ETHERAL, is…
More than a Million Children Provide Familial Care in the US
This post was originally published on this site The most recent statistics surrounding family caregiving in the United States are staggering. A 2005 National Alliance for Caregiving report estimates that 65.7 million Americans are familial caregivers. Of that number, more than 16 million care for people with dementia or Alzheimer’s disease. Shockingly, some of those…
Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows
This post was originally published on this site Keytruda (pembrolizumab), Merck‘s anti-PD-1 checkpoint blockade immunotherapy, failed to prolong the overall survival of patients with metastatic triple-negative breast cancer (TNBC) beyond that provided by chemotherapy agents, a Phase 3 trial shows. Checkpoint blockade immunotherapies are based on the principle of removing the “brakes” of our immune…
Trial Testing EDV Nanocells in Pancreatic, Other EGFR-positive Advanced Solid Cancers Now Dosing Patients
This post was originally published on this site A Phase 1/2 clinical trial has started dosing participants to test EnGeneIC‘s second-generation cytotoxic-loaded EDV nanocells as a treatment for EGFR-positive solid cancers who have exhausted all other therapeutic alternatives. The Carolyn Trial (ACTRN12619000385145), still recruiting participants at the Frankston Private Hospital in Victoria, Australia, is expected to…
Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma
This post was originally published on this site Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated approval of Ygalo (melflufen) to treat patients with triple-refractory multiple myeloma. Ygalo is a lipophilic peptide-conjugated alkylator that works by rapidly delivering a cancer-killing agent (an alkylating…
After Considering Patients’ Well-being, Rubraca Continues to Benefit Women with Recurrent Ovarian Cancer, Analysis Shows
This post was originally published on this site Maintenance therapy with Rubraca (rucaparib) tablets continues to benefit women with recurrent ovarian cancer after weighing in patients’ perceptions about their health, disease symptoms, and treatment toxicity, a retrospective analysis of Clovis Oncology‘s ARIEL3 Phase 3 clinical trial found. The data were presented recently at the International Society…
Agency Unveils RaDaR to Help Patient Groups Develop Rare Disease Registries
This post was originally published on this site RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
The Death of Denial
This post was originally published on this site I was helping Mom in the bathroom when suddenly she slumped over, unable to hold herself upright. Her hospice nurse was scheduled to come later that day but had previously offered to come sooner if needed, so I immediately contacted her. As soon as she saw Mom, she…
The Blonde in the Waiting Room
This post was originally published on this site A young woman weeped. Pretty blond hair swung in front of her face, but it didn’t hide her angst. From where I sat, I could feel the panic running though her body. It cut through the room like a chilly, wet breeze and crept into my lungs.…